The Festival of Genomics and Biodata 2026

Join Myllia at the Festival of Genomics and Biodata 2026 in London, England to explore single-cell perturbation data in primary human cell models

Myllia Biotechnology will be attending the Festival of Genomics and Biodata 2026 in London, England

Get in contact with Henrik Schmidt on site to learn more about Myllia’s high-content CRISPR screening platform in primary human cells enabling

(i) Unbiased drug target discovery
(ii) AI-ready perturbation data for foundation models

A fully integrated end-to-end screening platform to supercharge R&D programs:

1. Primary human cell models, incl. immune cells (CD4+/CD8+ T cells, myeloid cells), metabolic cells (adipocytes, hepatocytes), and epithelial cells
2. All CRISPR/Cas9 modalities for tailor-made Perturb-Seq/CROP-Seq screening
3. Proprietary sgRNA design algorithms for CRISPRn, CRISPRi and CRISPRa
4. High-content phenotypic readouts such as scRNA-Seq, CITE-Seq and FACS